Tue, Dec 28, 2021
"The approval of Covovax by DCGI is a significant milestone in strengthening our immunization efforts across India and LMICs. We are proud to deliver a highly-effective protein-based COVID-19 vaccine of more than 90 per cent efficacy rate, based on clinical data demonstrating a favorable safety profile.
More >
Fri, Nov 05, 2021
Novavax and its partner Serum Institute of India (SII) had said that they had received the first emergency use authorisation (EUA) for COVID-19 vaccine in Indonesia.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
